Brief: MedImpact Expands Access To Two Humira Biosimilars For New Patients
27/08/2024 18:23
Aug 27 (Reuters) - MedImpact Healthcare Systems:
* MEDIMPACT EXPANDS ACCESS TO TWO HUMIRA BIOSIMILARS FOR NEW
PATIENTS
* MEDIMPACT: EXPANDING ACCESS TO SIMLANDI & ADALIMUMAB-ADAZ
* MEDIMPACT: MEMBER COPAY, DEDUCTIBLE, AND OTHER FACTORS
WILL BE
SAME FOR BIOSIMILARS & HUMIRA
Source text for Eikon: ID:nBw3j3V9ka
Further company coverage: TEVA.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alvotech SA
See all newsBrief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Brief: Alvotech and Teva Secure U.S. Settlement Date For AVT06
India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar
Brief: UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea
U.S. STOCKS ON THE MOVE-Cummins, EPAM Systems, Qualcomm